share_log

康希諾生物：海外監管公告

CANSINOBIO: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 11 07:24
Summary by Moomoo AI
康希諾生物股份公司（「康希諾」）於2024年4月11日發布了由中信證券股份有限公司（「中信證券」）出具的2023年度持續督導跟蹤報告。報告顯示，康希諾2023年度營業收入較上年同期減少65.49%，凈虧損增加63.04%，主要由於新冠疫苗市場需求變化導致相關收入大幅下降，以及對新冠疫苗產品退回進行了核算及估計。公司為推廣流脑疫苗產品增加了銷售費用。報告期內，公司總資產和歸屬於母公司所有者的權益分別同比減少18.75%和21.84%。儘管面臨經營挑戰，康希諾仍在疫苗研發技術平台和產品管線方面保持創新，並在國際市場上具有競爭力。中信證券在持續督導期間未發現公司存在重大問題或重大違規事項，並確認募集資金使用合規。康希諾將繼續推進流脑產品的商業化進程，擴充產品線及銷售規模，以實現可持續發展。
康希諾生物股份公司（「康希諾」）於2024年4月11日發布了由中信證券股份有限公司（「中信證券」）出具的2023年度持續督導跟蹤報告。報告顯示，康希諾2023年度營業收入較上年同期減少65.49%，凈虧損增加63.04%，主要由於新冠疫苗市場需求變化導致相關收入大幅下降，以及對新冠疫苗產品退回進行了核算及估計。公司為推廣流脑疫苗產品增加了銷售費用。報告期內，公司總資產和歸屬於母公司所有者的權益分別同比減少18.75%和21.84%。儘管面臨經營挑戰，康希諾仍在疫苗研發技術平台和產品管線方面保持創新，並在國際市場上具有競爭力。中信證券在持續督導期間未發現公司存在重大問題或重大違規事項，並確認募集資金使用合規。康希諾將繼續推進流脑產品的商業化進程，擴充產品線及銷售規模，以實現可持續發展。
CONXINO BIOTECHNOLOGY CORPORATION (“CONXINO”) ISSUED ON 11 APRIL 2024 THE CONTINUING SUPERVISORY TRACKING REPORT FOR 2023 ISSUED BY CITIC SECURITIES CO., LTD. (“CITIC SECURITIES”). The report showed that Concino's 2023 operating income decreased 65.49% compared to the same period last year and increased its net loss by 63.04%, mainly due to changes in the COVID-19 vaccine market demand resulting in a significant decrease in related revenues and accounting and estimates for the return of COVID-19 vaccine products. The company has increased sales expenses for the promotion of cerebrospinal vaccine products. During the reporting period, the total assets of the company and the interests attributable to the owners of the parent company decreased by 18.75% and 21.84%, respectively. Despite operational challenges, Concino remains innovative in its vaccine R...Show More
CONXINO BIOTECHNOLOGY CORPORATION (“CONXINO”) ISSUED ON 11 APRIL 2024 THE CONTINUING SUPERVISORY TRACKING REPORT FOR 2023 ISSUED BY CITIC SECURITIES CO., LTD. (“CITIC SECURITIES”). The report showed that Concino's 2023 operating income decreased 65.49% compared to the same period last year and increased its net loss by 63.04%, mainly due to changes in the COVID-19 vaccine market demand resulting in a significant decrease in related revenues and accounting and estimates for the return of COVID-19 vaccine products. The company has increased sales expenses for the promotion of cerebrospinal vaccine products. During the reporting period, the total assets of the company and the interests attributable to the owners of the parent company decreased by 18.75% and 21.84%, respectively. Despite operational challenges, Concino remains innovative in its vaccine R&D technology platform and product pipeline and remains competitive in international markets. CITIC Securities did not detect any significant problems or significant violations by the company during the ongoing audit and confirmed compliance with the use of the raising funds. CONCHINO WILL CONTINUE TO ADVANCE THE COMMERCIALIZATION OF CEREBRAL PRODUCTS, EXPAND ITS PRODUCT LINE AND SALES SCALE TO ACHIEVE SUSTAINABILITY.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more